Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
The aim of the study was to investigate the potential mechanisms that interferencing of excision repair cross-complementing gene 1 (ERCC1) mediated by lentiviral vector in cisplatin-resistant ovarian cancer SKOV3/DDP cells. The human platinum-resistant ovarian carcinoma cell line SKOV3/DDP was transfected by pLVX-shRNA lentivirus. Interference efficiency for ERCC1 by lentiviruses transfection was detected by real-time polymerase chain reaction and western blot assay. CCK-8 assay was used for cell proliferation on cell resistance after transfection with ERCC1. Effects of cell apoptosis and cell cycles were detected by flow cytometry. The expression levels of ERCC1 were significantly suppressed in SKOV3/DDP cells after stably transfecting with shERCC1-recombinant plasmid. The results of cell viability assay demonstrated that interference with ERCC1 gene increased the sensitivity of SKOV3/DDP cells to cisplatin (p<0.01). ERCC1 gene-specific silencing promoted cell apoptosis of SKOV3/DDP cells (p<0.01) detected by flow cytometry. Cell cycle analysis results showed that the proportion of cells in G1 and S phase decreased, while the proportion of G2 phase cells increased in ERCC1-silencing cells. The differences were statistically significant (p<0.01), which demonstrated that stable interferencing with ERCC1 induced the cells arrest in G2 phase after being treated by DDP and silencing the expression of ERCC1 inhibited cell proliferation by preventing the progression of cell mitosis. ERCC1 gene silencing effectively reversed SKOV3/DDP cell resistance to cisplatin and increased sensitivity to cisplatin resistance in cisplatin-resistant ovarian cancer cells. Interference of ERCC1 promoted the apoptosis of SKOV3/DDP cells and prevented cell mitosis by inducing G0/G1 phase arrest. Thus, ERCC1 could be a potential therapeutic target for the therapy of cisplatin-resistant ovarian cancer and it would provide new ideas for epigenetic therapy of drug-resistant epithelial ovarian cancer.
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University , Guangzhou, China .
Pei
P
Du
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University , Guangzhou, China .
Xiaowei
X
Zhang
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University , Guangzhou, China .
Hualin
H
Liu
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University , Guangzhou, China .
Liquan
L
Chen
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology*; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D004720:Endonucleases / Q000235:genetics* / Q000378:metabolism; D005260:Female; D059585:G1 Phase Cell Cycle Checkpoints; D015870:Gene Expression; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000201:enzymology; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D034741:RNA, Small Interfering; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin